Display options
Cite
Kiang A, Weinberg VK, Cheung KH, et al. Long-term disease-specific and cognitive quality of life after intensity-modulated radiation therapy: a cross-sectional survey of nasopharyngeal carcinoma survivors. Radiat Oncol. 2016;11(1):127doi: 10.1186/s13014-016-0704-9.
Kiang, A., Weinberg, V. K., Cheung, K. H., Shugard, E., Chen, J., Quivey, J. M., & Yom, S. S. (2016). Long-term disease-specific and cognitive quality of life after intensity-modulated radiation therapy: a cross-sectional survey of nasopharyngeal carcinoma survivors. Radiation oncology (London, England), 11(1), 127. https://doi.org/10.1186/s13014-016-0704-9
Kiang, Alan, et al. "Long-term disease-specific and cognitive quality of life after intensity-modulated radiation therapy: a cross-sectional survey of nasopharyngeal carcinoma survivors." Radiation oncology (London, England) vol. 11,1 (2016): 127. doi: https://doi.org/10.1186/s13014-016-0704-9
Kiang A, Weinberg VK, Cheung KH, Shugard E, Chen J, Quivey JM, Yom SS. Long-term disease-specific and cognitive quality of life after intensity-modulated radiation therapy: a cross-sectional survey of nasopharyngeal carcinoma survivors. Radiat Oncol. 2016 Sep 26;11(1):127. doi: 10.1186/s13014-016-0704-9. PMID: 27671196; PMCID: PMC5036322.
Copy Download .nbib Format: NLM
Share it on

Radiat Oncol. 2016 Sep 26;11(1):127. doi: 10.1186/s13014-016-0704-9.

Long-term disease-specific and cognitive quality of life after intensity-modulated radiation therapy: a cross-sectional survey of nasopharyngeal carcinoma survivors.

Radiation oncology (London, England)

Alan Kiang, Vivian K Weinberg, Ka Ho Nicholas Cheung, Erin Shugard, Josephine Chen, Jeanne M Quivey, Sue S Yom

Affiliations

  1. Department of Radiation Oncology, University of California, San Francisco, USA.
  2. Department of Radiation Oncology, University of California, San Francisco, USA. [email protected].
  3. Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero St, MZ Bldg R H1031, Box 1708, San Francisco, CA, 94143-1708, USA. [email protected].

PMID: 27671196 PMCID: PMC5036322 DOI: 10.1186/s13014-016-0704-9

Abstract

BACKGROUND: There is a lack of data on quality of life in long-term survivors of nasopharyngeal carcinoma (NPC) who have been treated with intensity-modulated radiation therapy (IMRT). We characterized long-term disease-specific and cognitive QoL in NPC survivors after IMRT.

METHODS: We conducted a cross-sectional study of surviving patients diagnosed and treated for NPC at our center with curative-intent IMRT, with or without chemotherapy. Patients who were deceased, still undergoing treatment, with known recurrent disease, or treated with RT modality other than IMRT were excluded. QoL was measured by FACT-NP and FACT-Cog.

RESULTS: Between May and November 2013, 44 patients completed cognitive (FACT-Cog), general (FACT-G), and NPC-specific (NPCS) QoL assessments. Patients were categorized into 4 cohorts based on duration since IMRT (≤2.5, >2.5-6, >6-10, and >10-16 years). There was no significant difference in age (p = 0.20) or stage ((I/II vs III/IV: p = 0.78) among the cohorts. The 4 cohorts differed overall for all QoL measures (ANOVA: p < 0.02 for each), due to improved scores >2.5-6 years post-IMRT compared with ≤2.5 years post-IMRT (post hoc tests: p ≤ 0.04 for each). No differences were observed between >2.5-6 and >6-10 years post-IMRT, but lower mean FACT-Cog and NPCS scores were observed for >10 years compared to >2.5-6 years post-IMRT (post hoc: p < 0.05 for each).

CONCLUSIONS: All QoL measures were low during the initial recovery period (≤2.5 years) and were higher by 6 years post-IMRT. At >10 years post-IMRT, lower scores were observed in the domains of NPC-specific and cognitive QoL. Survivors of NPC, even if treated with IMRT, are at risk for detriment in domain-specific QoL measures at very long-term follow-up.

Keywords: Cognitive quality of life; Functional assessment of cancer therapy (FACT); General quality of life; Intensity-modulated radiation therapy (IMRT); Nasopharyngeal carcinoma (NPC)

References

  1. Radiother Oncol. 2011 Apr;99(1):1-5 - PubMed
  2. J Clin Exp Neuropsychol. 1998 Oct;20(5):684-93 - PubMed
  3. Neuro Oncol. 2013 Oct;15(10):1429-37 - PubMed
  4. Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):83-8 - PubMed
  5. J Neuropsychiatry Clin Neurosci. 2003 Winter;15(1):90-7 - PubMed
  6. Radiat Res. 2012 Jul;178(1):46-56 - PubMed
  7. Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):6-9 - PubMed
  8. J Clin Oncol. 2015 May 20;33(15):1653-9 - PubMed
  9. J Clin Oncol. 2007 Sep 10;25(26):4096-103 - PubMed
  10. Arch Otolaryngol Head Neck Surg. 2000 Apr;126(4):517-21 - PubMed
  11. Cancer. 2009 Jun 15;115(12):2605-16 - PubMed
  12. Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1528-33 - PubMed
  13. PLoS One. 2012;7(6):e36529 - PubMed
  14. Arch Neurol. 2000 Sep;57(9):1347-52 - PubMed
  15. J Clin Oncol. 2006 Mar 20;24(9):1415-20 - PubMed
  16. Cancer. 2003 Apr 15;97(8):2019-26 - PubMed
  17. Acta Oncol. 2004;43(2):153-60 - PubMed
  18. Int J Radiat Oncol Biol Phys. 1997 Jun 1;38(3):667-72 - PubMed
  19. J Neurol Neurosurg Psychiatry. 1989 Apr;52(4):488-92 - PubMed
  20. Lancet Oncol. 2012 Jun;13(6):568-9 - PubMed
  21. Clin Cancer Res. 2013 May 1;19(9):2294-300 - PubMed
  22. Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):725-31 - PubMed
  23. Am J Clin Oncol. 2011 Oct;34(5):478-82 - PubMed
  24. Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):499-505 - PubMed
  25. Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):722-6 - PubMed
  26. Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):870-7 - PubMed
  27. Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):1-7 - PubMed
  28. Am J Clin Oncol. 2007 Jun;30(3):271-7 - PubMed
  29. Science. 2003 Dec 5;302(5651):1760-5 - PubMed
  30. Curr Drug Targets. 2010 Nov;11(11):1413-22 - PubMed
  31. Neuropsychol Rehabil. 2016;26(3):392-409 - PubMed
  32. Psychooncology. 2009 Jun;18(6):606-14 - PubMed

Publication Types